RU2007116150A - Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола - Google Patents
Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола Download PDFInfo
- Publication number
- RU2007116150A RU2007116150A RU2007116150/04A RU2007116150A RU2007116150A RU 2007116150 A RU2007116150 A RU 2007116150A RU 2007116150/04 A RU2007116150/04 A RU 2007116150/04A RU 2007116150 A RU2007116150 A RU 2007116150A RU 2007116150 A RU2007116150 A RU 2007116150A
- Authority
- RU
- Russia
- Prior art keywords
- crystalline form
- crystalline
- ethenyl
- pyridin
- indazole
- Prior art date
Links
- RITAVMQDGBJQJZ-FMIVXFBMSA-N CNC(c(cccc1)c1Sc(cc1)cc2c1c(/C=C/c1ccccn1)n[nH]2)=O Chemical compound CNC(c(cccc1)c1Sc(cc1)cc2c1c(/C=C/c1ccccn1)n[nH]2)=O RITAVMQDGBJQJZ-FMIVXFBMSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Ophthalmology & Optometry (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (10)
1. Кристаллическая форма 6-[2-(метилкарбамоил)фенилсульфанил]-3-E-[2-(пиридин-2-ил)этенил]индазола, представленного формулой 1
или его фармацевтически приемлемая соль.
2. Кристаллическая форма по п.1, где кристаллическая форма выбрана из группы, состоящей из полиморфной формы I, формы II, формы III, формы IV, формы VI, формы VII, и формы VIII.
3. Кристаллическая форма по п.1, где кристаллическая форма представляет собой полиморф формы IV.
4. Кристаллическая форма по п.1, где порошковая рентгеновская дифрактограмма кристаллической формы содержит пики при величинах углов дифракции (2θ) 8,9±0,1 и 15,7±0,1.
5. Кристаллическая форма по п.1, где порошковая рентгеновская дифрактограмма кристаллической формы содержит пики при величинах углов дифракции (2θ) 8,9±0,1, 14,6±0,1, 15,7±0,1, и 19,2±0,1.
6. Кристаллическая форма по п.1, где порошковая рентгеновская дифрактограмма кристаллической формы содержит пики при величинах углов дифракции (2θ) по существу таких же, как показано на фигуре 4A.
7. Твердая форма 6-[2-(метилкарбамоил)фенилсульфанил]-3-E-[2-(пиридин-2-ил)этенил]индазола, или его фармацевтически приемлемой соли, где твердая форма содержит по меньшей мере две из следующих кристаллических форм: полиморфные формы I, II, III, IV, VI, VII и VIII.
8. Фармацевтическая композиция, содержащая кристаллическую форму по любому из пп.1-7.
9. Способ лечения патологического состояния млекопитающего, опосредованного протеинкиназной активностью, включающий в себя введение млекопитающему, нуждающемуся в этом, терапевтически эффективного количества фармацевтической композиции по п.8.
10. Способ по п.9, где патологическое состояние млекопитающего ассоциировано с фактором роста, клеточной пролиферацией или ангиогенезом.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US62466504P | 2004-11-02 | 2004-11-02 | |
| US60/624,665 | 2004-11-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2007116150A true RU2007116150A (ru) | 2008-11-10 |
Family
ID=35538878
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007116150/04A RU2007116150A (ru) | 2004-11-02 | 2005-10-21 | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20060094763A1 (ru) |
| EP (1) | EP1819696A1 (ru) |
| JP (1) | JP2008518904A (ru) |
| KR (1) | KR20070060145A (ru) |
| AR (1) | AR051945A1 (ru) |
| AU (1) | AU2005300317A1 (ru) |
| BR (1) | BRPI0517924A (ru) |
| CA (1) | CA2586177A1 (ru) |
| IL (1) | IL182580A0 (ru) |
| MX (1) | MX2007005273A (ru) |
| RU (1) | RU2007116150A (ru) |
| TW (1) | TW200630356A (ru) |
| WO (1) | WO2006048751A1 (ru) |
| ZA (1) | ZA200702976B (ru) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1885338A1 (en) * | 2005-05-19 | 2008-02-13 | Pfizer, Inc. | Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor |
| EP3252047B1 (en) * | 2007-04-05 | 2022-05-11 | Pfizer Products Inc. | Crystalline forms of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethenyl]indazole suitable for the treatment of abnormal cell growth in mammals |
| CN103826618A (zh) | 2011-09-30 | 2014-05-28 | 辉瑞大药厂 | N-甲基-2-[3-((e)-2-吡啶-2-基-乙烯基)-1h-吲唑-6-基硫烷基]苯甲酰胺的药物组合物 |
| JP2014533262A (ja) | 2011-11-11 | 2014-12-11 | ファイザー・インク | 慢性骨髄性白血病を治療するためのｎ−メチル−２−［３−（（ｅ）−２−ピリジン−２−イル−ビニル）−１ｈ−インダゾール−６−イルスルファニル］−ベンズアミド |
| EP2792360A1 (en) | 2013-04-18 | 2014-10-22 | IP Gesellschaft für Management mbH | (1aR,12bS)-8-cyclohexyl-11-fluoro-N-((1-methylcyclopropyl)sulfonyl)-1a-((3-methyl-3,8-diazabicyclo[3.2.1]oct-8-yl)carbonyl)-1,1a,2,2b-tetrahydrocyclopropa[d]indolo[2,1-a][2]benzazepine-5-carboxamide for use in treating HCV |
| CN104140414B (zh) * | 2013-05-07 | 2018-12-11 | 江苏豪森药业集团有限公司 | 阿昔替尼晶型的制备方法 |
| WO2015067224A1 (en) | 2013-11-08 | 2015-05-14 | Zentiva, K.S. | Salts of 6-[2-(methylcarbamoyl)phenylsulfanyl]-3-e-[2-(pyridin-2-yl)ethanyl] indazole |
| US10570202B2 (en) | 2014-02-04 | 2020-02-25 | Pfizer Inc. | Combination of a PD-1 antagonist and a VEGFR inhibitor for treating cancer |
| WO2016032927A1 (en) | 2014-08-25 | 2016-03-03 | Pfizer Inc. | Combination of a pd-1 antagonist and an alk inhibitor for treating cancer |
| CN112263677A (zh) | 2015-02-26 | 2021-01-26 | 默克专利股份公司 | 用于治疗癌症的pd-1/pd-l1抑制剂 |
| WO2016178150A1 (en) * | 2015-05-05 | 2016-11-10 | Shilpa Medicare Limited | Novel polymorphs of axitinib |
| US10869924B2 (en) | 2015-06-16 | 2020-12-22 | Merck Patent Gmbh | PD-L1 antagonist combination treatments |
| AU2017339856A1 (en) | 2016-10-06 | 2019-05-23 | Merck Patent Gmbh | Dosing regimen of avelumab for the treatment of cancer |
| WO2020003196A1 (en) * | 2018-06-28 | 2020-01-02 | Alembic Pharmaceuticals Limited | Pharmaceutical composition of axitinib |
| US20220370606A1 (en) | 2018-12-21 | 2022-11-24 | Pfizer Inc. | Combination Treatments Of Cancer Comprising A TLR Agonist |
| US20220194921A1 (en) | 2019-04-18 | 2022-06-23 | Synthon B.V. | Process for preparation of axitinib |
| EP3965743A1 (en) | 2019-05-09 | 2022-03-16 | Synthon B.V. | Pharmaceutical composition comprising axitinib |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| CN113943271B (zh) * | 2020-07-15 | 2023-11-14 | 鲁南制药集团股份有限公司 | 一种阿昔替尼晶型及其制备方法 |
| CN112174933A (zh) * | 2020-08-07 | 2021-01-05 | 天津理工大学 | 一种阿西替尼富马酸盐的新晶型及其制备方法 |
| CN114685437B (zh) * | 2020-12-25 | 2022-12-09 | 鲁南制药集团股份有限公司 | 阿昔替尼与糖精共晶 |
| CN114685436B (zh) * | 2020-12-25 | 2022-12-02 | 鲁南制药集团股份有限公司 | 阿昔替尼糖精共晶水合物 |
| CN114685431B (zh) * | 2020-12-26 | 2022-11-29 | 鲁南制药集团股份有限公司 | 一种阿昔替尼柠檬酸盐晶型 |
| CN114685438B (zh) * | 2020-12-28 | 2023-06-13 | 鲁南制药集团股份有限公司 | 一种阿昔替尼苹果酸新盐 |
| CN114685432B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 阿昔替尼盐晶型及其制备方法 |
| CN114685433B (zh) * | 2020-12-28 | 2022-11-25 | 鲁南制药集团股份有限公司 | 一种阿昔替尼香草酸共晶盐及其制备 |
| CN114685435B (zh) * | 2020-12-28 | 2023-01-31 | 鲁南制药集团股份有限公司 | 阿昔替尼马来酸盐晶型及其制备 |
| US20240117030A1 (en) | 2022-03-03 | 2024-04-11 | Pfizer Inc. | Multispecific antibodies and uses thereof |
| EP4282415A1 (en) | 2022-05-26 | 2023-11-29 | Genepharm S.A. | A stable tablet composition of axitinib |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20010306A1 (es) * | 1999-07-02 | 2001-03-29 | Agouron Pharma | Compuestos de indazol y composiciones farmaceuticas que los contienen utiles para la inhibicion de proteina kinasa |
| TWI262914B (en) * | 1999-07-02 | 2006-10-01 | Agouron Pharma | Compounds and pharmaceutical compositions for inhibiting protein kinases |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
-
2005
- 2005-10-21 CA CA002586177A patent/CA2586177A1/en not_active Abandoned
- 2005-10-21 EP EP05796896A patent/EP1819696A1/en not_active Withdrawn
- 2005-10-21 MX MX2007005273A patent/MX2007005273A/es not_active Application Discontinuation
- 2005-10-21 AU AU2005300317A patent/AU2005300317A1/en not_active Abandoned
- 2005-10-21 WO PCT/IB2005/003312 patent/WO2006048751A1/en active Application Filing
- 2005-10-21 RU RU2007116150/04A patent/RU2007116150A/ru not_active Application Discontinuation
- 2005-10-21 BR BRPI0517924-6A patent/BRPI0517924A/pt not_active IP Right Cessation
- 2005-10-21 JP JP2007538541A patent/JP2008518904A/ja active Pending
- 2005-10-21 KR KR1020077010040A patent/KR20070060145A/ko not_active Application Discontinuation
- 2005-10-31 US US11/264,493 patent/US20060094763A1/en not_active Abandoned
- 2005-11-01 TW TW094138274A patent/TW200630356A/zh unknown
- 2005-11-01 AR ARP050104569A patent/AR051945A1/es unknown
-
2007
- 2007-04-11 ZA ZA200702976A patent/ZA200702976B/xx unknown
- 2007-04-16 IL IL182580A patent/IL182580A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2008518904A (ja) | 2008-06-05 |
| BRPI0517924A (pt) | 2008-10-21 |
| EP1819696A1 (en) | 2007-08-22 |
| KR20070060145A (ko) | 2007-06-12 |
| WO2006048751A1 (en) | 2006-05-11 |
| ZA200702976B (en) | 2008-08-27 |
| IL182580A0 (en) | 2007-07-24 |
| AU2005300317A1 (en) | 2006-05-11 |
| TW200630356A (en) | 2006-09-01 |
| AR051945A1 (es) | 2007-02-21 |
| CA2586177A1 (en) | 2006-05-11 |
| US20060094763A1 (en) | 2006-05-04 |
| MX2007005273A (es) | 2007-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2007116150A (ru) | Полиморфные формы 6-[2-(метилкарбамоил)фенилсульфанил]-3-е-[2-[пиридин-2-ил)этенил]индазола | |
| JP2008518904A5 (ru) | ||
| JP5546717B2 (ja) | アリピプラゾール結晶質形態を調製する方法 | |
| EP1027050B1 (en) | 1,3-thiazoles as adenosine a3 receptor antagonists for the treatment of allergy, asthma and diabetes | |
| JP7035013B2 (ja) | アミノピリミジンｓｓａｏ阻害剤 | |
| KR100443850B1 (ko) | 헤테로시클릭 화합물의 도파민-ｄ３ 리간드로서의 용도 | |
| JP2008525434A (ja) | 新規な化合物 | |
| JP2014510133A (ja) | １−（３−シアノ−１−イソプロピル−インドール−５−イル）ピラゾール−４−カルボン酸の結晶形とその製造方法 | |
| JP2008266349A (ja) | ３−ピリジル基を有する置換チアゾール誘導体、その製造法および用途 | |
| EP2406226A1 (de) | Substituierte nicotinamide als kcnq2/3 modulatoren | |
| JP2008536833A5 (ru) | ||
| DE60220255T2 (de) | N-phenylarylsulfonamidverbindung, arzneimittel, das diese verbindung als wirkstoff enthält, zwischenprodukt für die verbindung und verfahren zu dessen herstellung | |
| HRP20151338T1 (hr) | [4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-[7-fluoro-1-(2-metoksi-etil)-4trifluorometoksi-1h-indol-3-il]metanon kao inhibitor triptaze mastocita | |
| WO2002066447A1 (en) | 4h-1,2,4-triazole-3(2h)-thione deratives as sphingomyelinase inhibitors | |
| NZ592413A (en) | Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound | |
| JP2008531701A5 (ru) | ||
| DE112012004878T5 (de) | Heterocyclische Dihydro-Fünfring-Ketonderivate als DHODH-Inhibitor und ihre Verwendung | |
| KR20130108985A (ko) | (6，7-디히드로-2-니트로-5ｈ-이미다졸[2,1-ｂ][1,3]옥사진-6-일)아미드 화합물, 그의 제조방법 및 용도 | |
| WO2006082107A1 (de) | Thiazolidinone als inhibitoren der polo like kinase (plk) als arzneimittel | |
| MX2007015970A (es) | Heterociclos sustituidos, su uso como un medicamento y preparaciones farmaceuticas que los comprenden. | |
| JP2010513489A5 (ru) | ||
| CA2772499A1 (en) | Polymorphic forms of manidipine | |
| CA2632149A1 (en) | Pyrimidine derivatives for the treatment of abnormal cell growth | |
| HU211290A9 (en) | 0-aryl ethers of morphinans | |
| CN107635981B (zh) | 用于诱导白色脂肪组织褐变的化合物和方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20091012 |